Know Cancer

or
forgot password

Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Kidney


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter

Thank you

Trial Information

Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Kidney


OBJECTIVES:

- Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in
patients with incurable carcinoma of the kidney.

- Describe response to, tolerance to, and side effects of this regimen in these patients.

OUTLINE: This is an open-label study.

Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1
by intravenous injection 6 times daily until the maximum tolerated dose is reached.

Treatment continues for at least 3 months in the absence of unacceptable toxicity or disease
progression. Patients achieving complete response (CR) continue treatment for an additional
8 months after achieving CR.

Tumors are measured every 2 months for 1 year and every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed stage IV adenocarcinoma or transitional cell carcinoma of
the kidney that is unlikely to respond to existing therapy

- Measurable disease by MRI or CT scan

- Tumor must be more than 2 cm for lymph nodes in head, neck, axillary, inguinal, or
femoral areas and at least 0.5 cm for other locations

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 60-100%

Life expectancy:

- At least 2 months

Hematopoietic:

- WBC at least 2,000/mm^3

- Platelet count at least 50,000/mm^3

Hepatic:

- No hepatic insufficiency

- Bilirubin no greater than 2.5 mg/dL

- SGOT and SGPT no greater than 5 times upper limit of normal

Renal:

- No renal insufficiency

- Creatinine no greater than 2.5 mg/mL

- No history of renal conditions that contraindicate high dosages of sodium

Cardiovascular:

- No known chronic heart failure

- No uncontrolled hypertension

- No history of congestive heart failure

- No history of other cardiovascular conditions that contraindicate high dosages of
sodium

Pulmonary:

- No severe lung disease, such as chronic obstructive pulmonary disease

Other:

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for 4 weeks after study
participation

- Not a high medical or psychiatric risk

- No concurrent nonmalignant systemic disease that would preclude therapy

- No active infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior immunotherapy

- No concurrent immunomodulatory agents

Chemotherapy:

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

- No concurrent antineoplastic agents

Endocrine therapy:

- Concurrent corticosteroids allowed

Radiotherapy:

- At least 8 weeks since prior radiotherapy and recovered

Surgery:

- Recovered from prior surgery

Other:

- Prior cytodifferentiating agents allowed

- No prior antineoplastons

Type of Study:

Interventional

Study Design:

Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Stanislaw R. Burzynski, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Burzynski Research Institute

Authority:

United States: Federal Government

Study ID:

CDR0000066564

NCT ID:

NCT00003520

Start Date:

August 1998

Completion Date:

Related Keywords:

  • Kidney Cancer
  • Transitional Cell Cancer of the Renal Pelvis and Ureter
  • stage IV renal cell cancer
  • recurrent renal cell cancer
  • metastatic transitional cell cancer of the renal pelvis and ureter
  • recurrent transitional cell cancer of the renal pelvis and ureter
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Carcinoma, Transitional Cell
  • Ureteral Neoplasms

Name

Location

Burzynski ClinicHouston, Texas  77055-6330